NeurAxis, Inc., will report financial results for its third quarter 2025, for the period ended September 30, 2025, on Tuesday, November 11, 2025, before market open.

NeurAxis, Inc., announced that it has received FDA 510(k) clearance for its proprietary percutaneous electrical nerve field stimulation (PENFS) technology for the treatment of functional abdominal pain (FAP) associated with functional dyspepsia (FD), and FD related nausea symptoms, in patients aged 8 years and older.

NeurAxis, Inc., announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.

NeurAxis, Inc., announced results for the second quarter 2025 for the period ended June 30, 2025.

NeurAxis, Inc., will report financial results for its second quarter 2025, for the period ended June 30, 2025, on Tuesday, August 12, 2025, before market open.

NeurAxis, Inc., today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), covering two health insurers, with approximately 700,000 total members in Connecticut and Massachusetts.

NeurAxis, Inc., has been officially incorporated into newly released clinical practice guidelines issued by the leading pediatric academic society for the treatment of Functional Abdominal Pain (FAP) in Irritable Bowel Syndrome (IBS).

NeurAxis, Inc., will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.

NeurAxis, Inc., today announced the closing of its previously announced registered direct offering of 1,538,461 shares of its common stock at a purchase price of $3.25 per share.

NeurAxis, Inc., today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,538,461 shares of its common stock at a purchase price of $3.25 per share in a registered direct offering priced at the market under NYSE American rules.